| abstract |
The present disclosure describes, for example, (a) long-acting IL-15 receptors in the treatment of a condition responsive to a therapy effective to provide immunostimulatory and sustained antitumor activity, for example. Provided are combination therapies, compositions, and kits, and related methods of preparation and use, comprising an agonist and (b) one or more antibodies (mAbs) that target tumor antigens. |